Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03240250
Other study ID # 3564
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 12, 2017
Est. completion date October 1, 2020

Study information

Verified date August 2017
Source Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

For the treatment of stage I-II NSCLC, two mini-invasive techniques are mostly utilized: uni-portal and three-portal VATS. In the uniportal approach, the injury on a single intercostal space could determine a lower level of pain than the three-portal approach, allowing a better postoperative course. Few studies in Literature compare these techniques, and most of them are retrospective. The main purpose of this randomized study is to compare uni-portal VATS with three-portal VATS, in terms of postoperative pain. Secondary objectives of the study are valutations of: - respiratory and functional capacity between the two groups - operative time - number of resected lymphnodes - intra and postoperative complications, such as conversions to open surgery, amount of bleeding, prolonged air leaks, surgical site infections, pulmonary complications.


Description:

Randomized cohort clinical trial, prospectic, monocentric. Procedure of randomization: the day before the operation, with the "Random Allocation Rule" technique Arm 1: pulmonary lobectomy and lymphoadenectomy with uni-portal VATS approach Arm 2: pulmonary lobectomy and lymphoadenectomy with three-portal VATS approach Misurations Total analgesic consumption, normalized to morphine milligrams, recorded in the 7 days following the operation. The choice of cumulative analgesic consumption as parameter of primary outcome is because pain valuation with VAS is significantly affected by individual variability. Secondary outcomes: measure of postoperative pain with NRS at 2,6,12,24 hours and at 2,3,4,5,30 days from sugery. A pain score will be assigned to each patient after the total amount of NRS. Respiratory function will be valuated with spirometry after 7 and 30 days from surgery, and compared with pre-operative tests. All intraoperative parameters will be compared between the two groups: operative time (skin to skin), proportion of conversions to open surgery, number of resected lymphnodes, amount of bleeding. Postoperative complications will be analyzed: rate of prolonged air leaks, surgical site infections, cardiac rythhm disfunctions, pulmonary complications, post-thoracotomy syndrome, as well as lenght of stay at the hospital.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date October 1, 2020
Est. primary completion date October 1, 2020
Accepts healthy volunteers No
Gender All
Age group 30 Years to 80 Years
Eligibility Inclusion Criteria: - Patients with cT1-2N0-1M0 NSCLC, maximum diameter 5cm - ASA (American Society of Anestesiology) score 1-2-3 Exclusion Criteria: - N2-N3 disease - Induction chemotherapy - Thoracic wall infiltration - Previous thoracic surgery - Important pleural adhesions - Severe COPD, asthma, interstitial lung disease - Liver, kidney or cardiac failure - Clotting disorders - Analgesic allergy - Sublobar resection, sleeve lobectomy, pneumonectomy - Chronic analgesic, oppioids or cortisonic use - Absence of informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
VATS uni-portal lobectomy and lymphoadenectomy
VATS uni-portal lobectomy and lymphoadenectomy
VATS three-portal lobectomy and lymphoadenectomy
VATS three-portal lobectomy and lymphoadenectomy, Copenhagen approach

Locations

Country Name City State
Italy Thoracic Surgery Unit - Fondazione IRCCS Ca' Granda Policlinico Milan Mi

Sponsors (1)

Lead Sponsor Collaborator
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of postoperative pain after uni-portal and three-portal VATS Total analgesic consumption, normalized to morphine milligrams, recorded in the 7 days following the operation. 7 days
Secondary Measure of postoperative pain with NRS at 2,6,12,24 hours and at 2,3,4,5,30 days from sugery. A pain score will be assigned to each patient after the total amount of NRS 30 days
Secondary Valuation of respiratory function Spirometry after 7 and 30 days from surgery, compared with pre-operative tests 30 days
Secondary Intraoperative parameters Operative time (skin to skin, minutes) 1 day
Secondary Intraoperative bleeding Amount of bleeding 1 day
Secondary Postoperative air leakage Rate of prolonged air leaks 15 days
Secondary Postoperative complications Cardiac rythhm disfunctions 1 month
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk